Trial Profile

A Phase 1a/b Study of ADRX-0706 in Subjects with Select Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 12 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ADRX-0706 (Primary)
Indications Advanced breast cancer; Carcinoma; Cervical cancer; Head and neck cancer; Male breast cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
Focus Adverse reactions; First in man
Sponsors Adcentrx Therapeutics

23 Apr 2025 According to an Adcentrx Therapeutics media release, Phase 1a dose escalation portion has been completed.
23 Apr 2025 According to an Adcentrx Therapeutics media release, data from this trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, The full abstract will be published by ASCO in conjunction with the Meeting.
23 Apr 2025 Interim clinical data from the Phase 1a portion presented in the Adcentrx Therapeutics Media Release

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com